Abstract
Since its approval by the U.S. Food and Drug Administration in late January 2018, 177Lu-labeled DOTATATE (Lutathera; Advanced Accelerator Applications, a Novartis company) has been used for the treatment of advanced somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors by
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Paper Title
Journal
Date
